Maze Therapeutics is a pioneering clinical-stage biopharmaceutical company located in South San Francisco, dedicated to leveraging human genetics to create groundbreaking, small molecule precision medicines aimed at treating patients with renal, cardiovascular, and metabolic diseases, including obesity. Through its innovative Compass platform, Maze Therapeutics expertly identifies and characterizes genetic variants linked to various diseases, allowing for a deep understanding of the biological pathways affecting specific patient populations via a process called variant functionalization. The company's unwavering commitment to discovering transformative therapies for both rare and common genetic conditions is underpinned by a dynamic culture that values creativity, teamwork, and integrity among its dedicated professionals. With a robust pipeline focused on chronic kidney disease, Maze Therapeutics is at the forefront of advancing healthcare through cutting-edge scientific research and development.